Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Lucrative Positions in the Advancing Position Market of 2024 - 2The Way to Recuperation: Defeating Dependence
- 3Oldest evidence of human fire-making discovered at site in England
- 4Indian Health Service is digging out of decades-old construction backlog for medical buildings
- 5Examination In progress into Abuse of Japanese Government-Supported Advance
- Top German court to rule on claims by Wirecard shareholders
- 2024 Style: The It-Things You Want in Your Closet
- Vote In favor of Your Favored Language Interpretation Administration
- Help Your Efficiency with These Work area Updates
- 'Wuthering Heights' trailer features Margot Robbie and Jacob Elordi in a steamy forbidden romance
- Israel and Lebanon's Hezbollah continue to trade attacks
- ONE returns to Red Sea with new service
- 1,000-mile Saharan dust storm, from the sky and from the ground
- I tried a macho, creatine-loaded cereal “for men.” Did I mention I'm a woman?
